Study guide

5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

Key Takeaways Explain This Topic AI

Options counseling is nondirective and covers parenting, adoption, and abortion; clinicians with conscientious objections must still give accurate information and a timely referral.

The FDA-approved medication abortion regimen is mifepristone 200 mg orally followed 24–48 hours later by misoprostol 800 mcg buccally, through 70 days (10 weeks) of gestation, with about 95%–98% complete abortion.

Mifepristone contraindications include confirmed or suspected ectopic pregnancy, an IUD in place, chronic adrenal failure, long-term systemic corticosteroids, bleeding disorders or anticoagulation, and inherited porphyria.

Since the 2023 REMS modification, mifepristone has no in-person dispensing requirement and may be dispensed by certified pharmacies or by mail, although state laws after Dobbs (2022) restrict abortion in many states.

ACOG (2024) suggests forgoing routine Rh testing and Rho(D) immune globulin for abortion before 12 weeks, and an implant can be placed the same day mifepristone is taken.

Last updated: October 2026

Options Counseling

When a patient has an unintended or uncertain pregnancy, the WHNP:

Confirms the pregnancy and estimates gestational age from the LMP. Ultrasound is needed when dating is uncertain or ectopic risk factors or symptoms are present.

Provides nondirective counseling on all three options: continuing the pregnancy and parenting , continuing the pregnancy and placing for adoption , and abortion . The patient's values guide the decision.

Screens for coercion and safety , including reproductive coercion and intimate partner violence, and talks with the patient alone.

Refers promptly for the chosen option, because both medication and procedural abortion are safer and more available earlier in pregnancy. A clinician with a conscientious objection must still give accurate information and a timely referral, and must never delay emergency care.

The Legal Landscape

Dobbs v. Jackson Women's Health Organization (June 24, 2022) ended the federal constitutional right to abortion, so legality now depends on state law : some states ban abortion with narrow exceptions, some set gestational limits, and some protect access and clinicians through shield laws. Rules on telehealth prescribing, parental involvement for minors, and waiting periods also vary by state. The WHNP must know the law where they practice and where the patient lives.

  • Medication Abortion
  • Standard Regimen

Mifepristone 200 mg orally , a progesterone receptor antagonist that detaches the pregnancy and softens the cervix, then

Misoprostol 800 mcg buccally (or vaginally or sublingually) 24–48 hours later , a prostaglandin E1 analog that causes uterine contractions and expulsion.

FDA-approved through 70 days (10 weeks) from the LMP; complete abortion occurs in about 95%–98% . Evidence-based protocols extend use to 77 days with a second misoprostol dose.

Misoprostol-only regimens (800 mcg every 3 hours for several doses) are less effective but are used where mifepristone is unavailable.

Contraindications to Mifepristone

Confirmed or suspected ectopic pregnancy : mifepristone does not treat ectopic pregnancy.

An IUD in place (remove it first).

Chronic adrenal failure or long-term systemic corticosteroid therapy.

Hemorrhagic disorders or current anticoagulant therapy.

Inherited porphyria.

Allergy to mifepristone or misoprostol.

Counseling: Expected Effects and Warning Signs

Cramping and bleeding heavier than a menstrual period are expected, usually starting within hours of misoprostol, along with possible nausea, diarrhea, and transient fever or chills on the misoprostol day. NSAIDs relieve cramps. Seek care for:

Soaking two thick pads per hour for 2 consecutive hours .

Fever of 100.4 °F (38 °C) or higher lasting more than 4 hours in the days after treatment, or feeling ill, weak, or nauseated several days later (rare serious infection, including Clostridium sordellii sepsis, can occur without fever). A brief temperature rise on the misoprostol day is expected.

No bleeding within 24 hours of misoprostol, which may mean an ongoing or ectopic pregnancy.

Follow-Up

Confirm completion by a symptom check plus a serial serum hCG decline, ultrasound, or a low-sensitivity home pregnancy test about 4 weeks later. An ongoing pregnancy needs repeat medication or aspiration; persistent retained tissue with heavy bleeding may need aspiration.

Regulation

Mifepristone is dispensed under an FDA Risk Evaluation and Mitigation Strategy (REMS) . The January 2023 REMS modification removed the in-person dispensing requirement and created pharmacy certification , so certified prescribers can have mifepristone dispensed by certified pharmacies, including by mail. As of 2026 this framework remains in effect: in May 2026 the Supreme Court declined to let a lower-court order reinstate in-person dispensing, and an FDA review of the REMS that began in 2025 is ongoing. State laws can still prohibit or restrict prescribing.

Procedural (In-Clinic) Abortion

Aspiration (manual or electric vacuum): Used in the first trimester and early second trimester; takes about 5–10 minutes under a paracervical block, with or without sedation; complete in more than 99%.

Dilation and evacuation (D&E): Used in the second trimester after cervical preparation with misoprostol or osmotic dilators.

Complications are uncommon: retained tissue, hemorrhage, infection (reduced by routine prophylactic doxycycline), and rarely perforation or cervical injury. Legal induced abortion has a lower mortality rate than continuing a pregnancy to birth.

Rh Status

ACOG's 2024 Clinical Practice Update suggests forgoing routine Rh testing and Rho(D) immune globulin for abortion or pregnancy loss before 12 weeks , because fetal red-cell exposure is too small to cause sensitization; it may be offered on request. At 12 weeks or later, give anti-D immune globulin to unsensitized Rh(D)-negative patients.

Contraception After Abortion

  • Method Timing After Medication Abortion Timing After Procedural Abortion
  • Implant Same day as mifepristone Same day
  • DMPA Same day (may slightly lower medication-abortion success; counsel) Same day
  • Pills, patch, ring Within a week of misoprostol Same day

IUD (LNG or copper) Once complete expulsion is confirmed Immediately after aspiration (US MEC Category 1 in the first trimester)

Fertility returns quickly; ovulation can occur within about 2 weeks.

Adoption and Parenting

Adoption: Discuss open (ongoing contact) versus closed adoption, the birth parent's rights, and the timing of relinquishment, which is set by state law and allowed only after birth. Safe Haven laws let a parent leave a newborn at designated locations within a state-defined period.

Parenting: Start prenatal care, folic acid, and screening promptly, and connect the patient with WIC, Medicaid, and social support.